Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eric D. Raftery"'
Autor:
Isaac Benavides, Eric D. Raftery, Alexandra G. Bell, Declan Evans, Wendell A. Scott, K. N. Houk, Timothy J. Deming
Publikováno v:
Journal of the American Chemical Society. 144(9)
Via the design of a new, soluble poly(
Publikováno v:
Chemistry, an Asian journal, vol 13, iss 22
Biologically occurring non-canonical di-α-amino acids were converted into new di-N-carboxyanhydride (di-NCA) monomers in reasonable yields with high purity. Five different di-NCAs were separately copolymerized with tert-butyl-l-glutamate NCA to obta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe234256cefa4491f6e5fcdb7d1ca5aa
https://escholarship.org/uc/item/2jh9m3mb
https://escholarship.org/uc/item/2jh9m3mb
Autor:
Kyle Tamshen, Heather D. Maynard, Uland Y. Lau, Emma M. Pelegri-O’Day, Nicholas M. Matsumoto, Eric D. Raftery
Publikováno v:
Bioconjugate chemistry. 29(11)
Poly(ethylene glycols) (PEGs) with protein-reactive end-groups are widely utilized in bioconjugation reactions. Herein, we describe the use of ring-opening metathesis polymerization (ROMP) to synthesize unsaturated protein-reactive PEG analogs. These
Autor:
Berkley E. Gryder, Michael K. Rood, Eric D. Raftery, Shafiq A. Khan, Paulette Dillard, Adegboyega K. Oyelere, Warren M. Meyers, Michelle J. Akbashev
Publikováno v:
ACS Chemical Biology. 8:2550-2560
Diverse cellular processes relevant to cancer progression are regulated by the acetylation status of proteins. Among such processes is chromatin remodeling via histone proteins, controlled by opposing histone deacetylase (HDAC) and histone acetyltran
Autor:
Marcie Rice, Eric D. Raftery, Berkley E. Gryder, Adegboyega K. Oyelere, Michael K. Rood, Bahareh Azizi, Kenyetta A. Johnson, Vishal Patil, Donald F. Doyle, Li-Pan D. Yao
Publikováno v:
Journal of Medicinal Chemistry. 56:5782-5796
We describe a set of novel histone deacetylase inhibitors (HDACi) equipped with either an antagonist or an agonist of the estrogen receptor (ER) to confer selective activity against breast cancers. These bifunctional compounds potently inhibit HDAC a
Autor:
Subhasish Tapadar, Eric D. Raftery, Idris O. Raji, Celinah Mwakwari, Shaghayegh Fathi, Adegboyega K. Oyelere
Publikováno v:
Cancer Research. 73:B57-B57
Histone deacetylase (HDAC) inhibition is a promising therapeutic strategy for cancer treatment because HDAC inhibitors have shown the ability to arrest proliferation of nearly all transformed cell lines. Recently, we have reported a new class of hydr